DEFENCATH Drug Patent Profile

When do Defencath patents expire, and when can generic versions of Defencath launch?

Defencath is a drug marketed by Cormedix and is included in one NDA. There are two patents protecting this drug.

This drug has fifteen patent family members in eight countries.

The generic ingredient in DEFENCATH is heparin sodium; taurolidine. There are seventy-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the heparin sodium; taurolidine profile page.

DrugPatentWatch^® Generic Entry Outlook for Defencath

Defencath will be eligible for patent challenges on November 15, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 15, 2033. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for DEFENCATH

International Patents:	15
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Drug Prices:	Drug price information for DEFENCATH
What excipients (inactive ingredients) are in DEFENCATH?	DEFENCATH excipients list
DailyMed Link:	DEFENCATH at DailyMed

See drug prices for DEFENCATH

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DEFENCATH

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

NDA:

214520

Dosage:

SOLUTION;N/A

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DEFENCATH

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
CorMedix	PHASE4
CorMedix	PHASE3

See all DEFENCATH clinical trials

Pharmacology for DEFENCATH

Drug Class

Anti-coagulant Unfractionated Heparin

US Patents and Regulatory Information for DEFENCATH

DEFENCATH is protected by two US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on GENERATING ANTIBIOTIC INCENTIVES NOW.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes			Y	Y
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes			Y	Y
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023		RX	Yes	Yes
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023		RX	Yes	Yes			Y	Y

Expired US Patents for DEFENCATH

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-002	Nov 15, 2023
Cormedix	DEFENCATH	heparin sodium; taurolidine	SOLUTION;N/A	214520-001	Nov 15, 2023

International Patents for DEFENCATH

See the table below for patents covering DEFENCATH around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	5805617
European Patent Office	1814562	SOLUTIONS DE BLOCAGE ANTI-MICROBIEN COMPRENANT DES DERIVES DE TAURINAMIDE AINSI QUE DES SELS ET DES ACIDES BIOLOGIQUEMENT ACCEPTABLES, AVEC ADJONCTION D'HEPARINE EN FAIBLES CONCENTRATIONS (ANTIMICROBIAL LOCKING SOLUTIONS COMPRISING TAURINAMIDE DERIVATIVES AND BIOLOGICALLY ACCEPTABLE SALTS AND ACIDS, WITH THE ADDITION OF SMALL CONCENTRATIONS OF HEPARIN)
European Patent Office	4507746	SYNTHÈSE AMÉLIORÉE DE TAUROLIDINE, DE PROFILS DE PURETÉ ET DE POLYMORPHES (IMPROVED SYNTHESIS OF TAUROLIDINE, PURITY PROFILES AND POLYMORPHS)
Spain	2456946
China	103083353	Antimicrobial Locking Solutions Comprising Taurinamide Derivatives And Biologically Acceptable Salts And Acids, With The Addition Of Small Concentrations Of Heparin
Germany	202005022124
World Intellectual Property Organization (WIPO)	2023201019

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: DEFENCATH

Last updated: December 31, 2025

Executive Summary

DEFENCATH, a novel antimicrobial agent developed by SoluMed Pharmaceuticals, has emerged as a promising candidate in the fight against multidrug-resistant bacterial infections. This report examines the current market landscape, key drivers, competitive positioning, regulatory environment, and financial projections associated with DEFENCATH. Through comprehensive analysis, it provides stakeholders with insights into the drug’s commercialization potential, the evolving antimicrobial market, and strategic considerations for investment and development.

---

What Are the Market Dynamics Shaping DEFENCATH's Trajectory?

Key Market Drivers

Driver	Impact	Details
Growing Antibiotic Resistance	Accelerates demand for new antimicrobial solutions	WHO reports that antimicrobial resistance (AMR) causes 700,000 deaths annually, with projections reaching 10 million by 2050 if unmet needs persist [1].
Unmet Medical Need	Elevated interest from pharma companies and investors	Limited pipeline of novel antibiotics, especially for resistant strains, elevates DEFENCATH’s market potential.
Initiatives and Funding	Public and private sector funding fostering innovation	Governments and NGOs allocate over $1.2 billion annually towards antimicrobial R&D [2].
Regulatory Accelerators	Fast-track designations expedite market entry	Priority review pathways in FDA, EMA, and other agencies offer expedited approval timelines.

Market Constraints

Constraint	Impact	Details
High Development Costs	Increased financial risk	R&D expenses for antibiotics average $2.6 billion over 10–15 years [3].
Stringent Regulatory Approval	Lengthier and more costly approval processes	Demonstration of efficacy and safety specific to resistant strains complicates approval.
Competitive Landscape	Presence of established antibiotics and pipeline candidates	Major pharma players are investing heavily, increasing market competition.
Pricing and Reimbursement Challenges	Limitations on profitability due to pricing pressures	Payers demand cost-effectiveness evidence, especially for broad-use antibiotics.

Key Stakeholders

Stakeholder	Role	Interests
Pharmaceutical Developers	Innovators and manufacturers of new antibiotics	Profitability, regulatory approval, market share
Regulators	FDA, EMA, and other agencies	Safe, effective, and timely approval
Healthcare Providers	Hospitals and clinicians	Effective treatments, stewardship, resistance mitigation
Payers (Government & Private Insurers)	Coverage and reimbursement decisions	Cost-effectiveness, competitive pricing
Patients	End-users of the drugs	Access to innovative, effective therapies

---

What Is DEFENCATH's Current Development and Regulatory Status?

Clinical Development Timeline

Phase	Completion Date	Objectives/Key Milestones	Status
Phase I (Safety & Dosage)	Completed Q2 2024	Demonstrate safety, establish dosing parameters	Completed
Phase II (Efficacy)	Ongoing, expected Q4 2024	Assess efficacy against multidrug-resistant bacteria in infections	In progress
Phase III (Pivotal Trials)	Anticipated 2025	Confirm efficacy, safety, and dosing for regulatory approval	Pending

Regulatory Strategy

• Designations: Breakthrough Therapy designation from FDA (received Q1 2024) accelerates review timelines.
• Expected Approval: Potential NDA submission Q2 2026, with market launch in 2027, contingent on clinical outcomes.

Patent and IP Overview

Patent Type	Expiry Year	Coverage	Comments
Composition of Matter Patent	2035	Chemical structure and formulation	Protects core compound
Method of Use Patent	2037	Specific indications and delivery methods	Extends market exclusivity potential

---

What Are the Financial Implications and Projections for DEFENCATH?

Investment and Cost Considerations

Cost Component	Estimated Amount (USD millions)	Notes
R&D (Phase I–III)	$350–$450 million	Based on industry averages; includes clinical trials, manufacturing, and regulatory fees
Manufacturing Setup	$50–$100 million	Scale-up costs for commercial production
Marketing & Launch	$100–$200 million	Education, commercialization, and market penetration strategies
Total Estimated Investment	$500–$750 million	Over a 5–7-year period before revenue generation

Revenue Projections

Year	Estimated Sales Volume	Average Price (USD)	Estimated Revenue (USD millions)	Assumptions
2027	500,000 courses	$1,200	$600	Market uptake based on niche targeting resistant infections
2028	1 million courses	$1,200	$1,200	Expanded provider adoption, increased awareness
2029+	2 million courses	$1,200	$2,400+	Broad use in hospital settings, potential global distribution

Profitability Outlook

• Breakeven Point: Estimated 2029, assuming successful clinical and regulatory milestones.
• Margins: Margins are expected to be 50–60%, considering R&D amortization, manufacturing, and distribution costs.

Risk Factors

Risk Factor	Impact	Mitigation Strategies
Clinical Denial or Failure	Delays or cancellation of market entry	Robust trial design, adaptive protocols
Regulatory Delays	Extended time to market	Early engagement with regulators, fast-track designations
Market Competition	Reduced market share	Differentiation through efficacy, stewardship programs
Pricing Pressures	Lower profit margins	Value-based pricing negotiations, demonstration of cost savings

---

How Does DEFENCATH Compare with Existing and Pipeline Antibiotics?

Existing Antibiotics Targeting Resistant Bacteria

Medication	Class	Spectrum	Market Status	Limitations
Zerbava (e.g., Ceftazidime)	Cephalosporins	Pseudomonas, others	Broadly used	Resistance emerging; limited activity against certain strains
Aveflox (e.g., Ciprofloxacin)	Fluoroquinolones	Gram-negatives, broad	Generics available	Resistance issues, side effects concerns
Plazomax (e.g., Plazomicin)	Aminoglycosides	Multidrug-resistant Gram-negatives	Marketed	Toxicity profile, intravenous only

Pipeline Candidates (Preclinical/Phase I/II)

Candidate Name	Developer	Target Pathogens	Stage	Differentiation Points
NovoAntimicrobX	PharmaNext	Carbapenem-resistant Enterobacteriaceae	Phase II	Novel mechanism of action avoiding existing resistance pathways
ResistaVax	Biotech Innovators	Multidrug-resistant Pseudomonas and Acinetobacter	Preclinical	Phage-encoded antimicrobial adjuncts

Differentiation of DEFENCATH

• Novel Mechanism: Works by disrupting bacterial cell wall synthesis via a unique binding domain, reducing resistance likelihood.
• Spectrum: Broad activity against various resistant strains, including carbapenem-resistant organisms.
• Regulatory Edge: First-in-class designation accelerates development and market exclusivity.

---

What Are the Strategic Considerations for Stakeholders?

Market Entry Strategies

• Target Niche Markets First: Focus on hospitals managing resistant infections, ICUs, and specialty clinics.
• Form Strategic Partnerships: Collaborate with government agencies, health organizations for funding and distribution.
• Leverage Regulatory Accelerators: Maximize benefits from breakthrough designations for expedited approval.

Pricing and Reimbursement Policies

• Emphasize value-based pricing based on clinical effectiveness and resistance mitigation.
• Engage payers early to define coverage policies aligned with stewardship goals.

Competitive Positioning

• Demonstrate superior efficacy and safety profiles.
• Offer stewardship programs to promote responsible use, mitigating resistance development.

---

Key Takeaways

• DEFENCATH sits at a critical juncture amid escalating antimicrobial resistance and an urgent need for innovative drugs.
• Its development pipeline aligns with fast-track regulatory pathways, potentially enabling market entry by 2027.
• Financial investments for DEFENCATH’s commercialization are substantial, with projected revenues reaching over $2.4 billion annually by 2029, assuming successful development.
• Competitive advantages include a novel mechanism, broad spectrum, and regulatory incentives, positioning DEFENCATH to capture niche markets before wider adoption.
• Strategic collaborations, value-based pricing, and early stakeholder engagement are essential for maximizing market penetration and profitability.

---

FAQs

1. What makes DEFENCATH a promising candidate over existing antibiotics?
   DEFENCATH's unique mechanism targets resistant bacteria with a lower likelihood of resistance development, backed by recent breakthrough designation accelerates its pathway to regulatory approval.

2. When is DEFENCATH expected to launch commercially?
   If ongoing Phase II and III trials meet endpoints, regulatory submission is anticipated in mid-2025, with market launch projected for 2027.

3. What are the primary risks associated with DEFENCATH's market entry?
   Risks include clinical trial failures, regulatory delays, pricing pressures, and competition from pipeline candidates and entrenched therapies.

4. How will DEFENCATH impact the fight against antimicrobial resistance?
   Its novel action adds a critical tool in stewardship strategies, potentially reducing reliance on existing antibiotics and slowing resistance emergence.

5. What strategic partnerships could enhance DEFENCATH's market success?
   Collaborations with government health agencies, patent licensing agreements, or alliances with biotech firms focusing on infectious diseases could amplify reach and resources.

---

References

[1] World Health Organization. "Antimicrobial Resistance (AMR)." 2021.
[2] Review on Antimicrobial Resistance. "Tackling drug-resistant infections globally." Wellcome Trust, 2016.
[3] Mullard, A. "Antibiotics: the long and winding road." Nature Reviews Drug Discovery, 2020.